FDA approves Merck’s KEYTRUDA® (pembrolizumab) for treatment of PMBCL
Merck announced the FDA has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or who have relapsed after two or more prior lines of therapy. June 13, 2018